Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - ESG Rating
EMCURE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Emcure Pharmaceuticals has received an ESG (Environmental, Social, and Governance) rating of 21 for Financial Year 2024-25 from NSE Sustainability Ratings & Analytics Limited, a SEBI registered ESG Rating Provider. The rating was assigned voluntarily and independently based on publicly available information. The company received formal intimation of this rating on May 7, 2026, and made the disclosure on May 8, 2026 in compliance with SEBI Listing Regulations. This is a proactive sustainability disclosure and does not impact financial performance or operations directly.
The ESG rating is a non-financial metric that may influence ESG-focused investors and institutional funds. It does not directly affect revenue or profitability but signals the company's commitment to sustainability practices.